Stock Analysis

uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year

  •  Updated
NasdaqGS:QURE
Source: Shutterstock

Today is shaping up negative for uniQure N.V. (NASDAQ:QURE) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting analysts have soured majorly on the business.

Following the downgrade, the consensus from 17 analysts covering uniQure is for revenues of US$80m in 2022, implying a stressful 85% decline in sales compared to the last 12 months. After this downgrade, the company is anticipated to report a loss of US$3.14 in 2022, a sharp decline from a profit over the last year. Yet before this consensus update, the analysts had been forecasting revenues of US$127m and losses of US$2.65 per share in 2022. Ergo, there's been a clear change in sentiment, with the analysts administering a notable cut to this year's revenue estimates, while at the same time increasing their loss per share forecasts.

View our latest analysis for uniQure

earnings-and-revenue-growth
NasdaqGS:QURE Earnings and Revenue Growth May 4th 2022

The consensus price target was broadly unchanged at €52.26, perhaps implicitly signalling that the weaker earnings outlook is not expected to have a long-term impact on the valuation. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic uniQure analyst has a price target of €85.07 per share, while the most pessimistic values it at €34.00. This is a fairly broad spread of estimates, suggesting that the analysts are forecasting a wide range of possible outcomes for the business.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We would highlight that sales are expected to reverse, with a forecast 92% annualised revenue decline to the end of 2022. That is a notable change from historical growth of 80% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 11% per year. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - uniQure is expected to lag the wider industry.

The Bottom Line

The most important thing to note from this downgrade is that the consensus increased its forecast losses this year, suggesting all may not be well at uniQure. Regrettably, they also downgraded their revenue estimates, and the latest forecasts imply the business will grow sales slower than the wider market. We're also surprised to see that the price target went unchanged. Still, deteriorating business conditions (assuming accurate forecasts!) can be a leading indicator for the stock price, so we wouldn't blame investors for being more cautious on uniQure after the downgrade.

That said, the analysts might have good reason to be negative on uniQure, given concerns around earnings quality. Learn more, and discover the 2 other flags we've identified, for free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

What are the risks and opportunities for uniQure?

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases.

View Full Analysis

Rewards

  • Trading at 89.1% below our estimate of its fair value

  • Revenue is forecast to grow 37.82% per year

Risks

  • Significant insider selling over the past 3 months

  • Currently unprofitable and not forecast to become profitable over the next 3 years

View all Risks and Rewards

Share Price

Market Cap

1Y Return

View Company Report